All In Biotech

Drug Trial Radar · NCT06611319

ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,932 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,932

Planned (sponsor's estimate)

Start

Nov 26, 2024

Primary completion

Mar 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Prof. Stavros Konstantinides, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Surgical hip replacement (total hip arthroplasty, THA) is associated with a high risk of venous thromboembolism, but the appropriate duration of postoperative medical thromboprophylaxis ("anticoagulation") remains highly controversial. The international randomized controlled trial (RCT) "ENhanced recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis after primary Hip Arthroplasty" (ENABLE-Hip) will enroll patients undergoing elective THA that are eligible for early mobilization after surgery. The trial will compare a regimen of short-duration (10-day) postoperative anticoagulation (experimental group) to standard-duration (35-day) postoperative anticoagulation (control group) using the direct oral anticoagulant Rivaroxaban (brand name: Xarelto) at the recommended dose. Thus, ENABLE-Hip will be the first major RCT to directly test an overall reduction in the duration of post-THA thromboprophylaxis instead of replacing one antithrombotic drug or regimen by another. Follow-up visits after hospital discharge will be on day 35 and on day 90 after surgery. The primary outcome is acute symptomatic proximal deep vein thrombosis, or symptomatic or fatal pulmonary embolism, within 90 days after surgery. If ENABLE-Hip will demonstrate 'non-inferiority' of the experimental intervention, its benefits will be obvious, as patients are spared many days of unnecessary (and potentially harmful in terms of bleeding risk) anticoagulation.

Conditions

  • Hip Arthroplasty, Total
  • Prevention of Venous Thromboembolism

Interventions

  • Prevention of Venous ThromboembolismDrug

    Direct oral anticoagulant

  • Placebo Oral TabletDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoint is the rate of acute symptomatic or fatal VTETime frame: within 90 days after surgery

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Kepler University Medical Center, Orthopedics and Traumatology

    Linz, Upper Austria, Austria · Recruiting

  • Evangelical Forest Hospital Berlin - Orthopaedics and Trauma Surgery

    Berlin, Germany · Recruiting

  • Sana Clinics Sommerfeld, Dpt. for Surgical Orthopaedics

    Kremmen, Brandenburg, Germany · Recruiting

  • GPR Rüsselsheim Health and Care Center

    Rüsselsheim am Main, Hesse, Germany · Recruiting

  • University Medical Center Mainz, Center for Orthopedics and Trauma Surgery

    Mainz, Rhineland-Palatine, Germany · Recruiting

  • University Medical Center Dresden, University Center for Orthopaedics, Trauma & Plastic Surgery

    Dresden, Saxony, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.